Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.

Clinical lymphoma, myeloma & leukemia - 1 Feb 2013

Bougherara Houcine, Georgin-Lavialle Sophie, Damaj Gandhi, Launay Jean-Marie, Lhermitte Ludovic, Auclair Christian, Arock Michel, Dubreuil Patrice, Hermine Olivier, Poul Marie-Alix

Abstract excerpt

BACKGROUND: Systemic mastocytosis (SM) is a heterogeneous disease that displays variable aggressivity. Adults with SM frequently have a D816V mutation in the tyrosine kinase (TK) receptor gene KIT. We previously reported that, in a Chinese hamster ovarian cell model expressing exogenous KIT variants, constitutive activating KIT mutations induced intracellular mislocalization of KIT reversed by inhibition of KIT...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Cell Membrane

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dasatinib

Share to Mastocytosis, Systemic

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Thiazoles

Source

Identifiers

PMID: 23127495
DOI: 10.1016/j.clml.2012.08.004

Genes

KIT

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications.PMID 23127495Read ↗

An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.Semantic proximity Read ↗

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.Semantic proximity Read ↗

KITD816V mutation in blood for the diagnostic screening of systemic mastocytosis and mast cell activation syndromes.Semantic proximity Read ↗

KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis.Semantic proximity Read ↗

High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V.Semantic proximity Read ↗

KIT D816V is dimerization-independent and activates downstream pathways frequently perturbed in mastocytosis.Semantic proximity Read ↗

Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic Mastocytosis.Semantic proximity Read ↗

Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Semantic proximity Read ↗

KIT mutations in mastocytosis and their potential as therapeutic targets.Semantic proximity Read ↗

Tyrosine Kinase Inhibition in Mastocytosis: KIT and Beyond KIT.Semantic proximity Read ↗

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy.Semantic proximity Read ↗

KIT D816V–mutated bone marrow mesenchymal stem cells in indolent systemic mastocytosis are associated with disease progressionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.